$AVIR News
Last published 2d ago
- 2d agoAVIRAtea Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoAVIRAtea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection
- 2d agoAVIRAtea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection Phase 3 C-FORWARD Trial for HCV on Track for
- 2d agoAVIRAtea Pharmaceuticals Third Quarter 2026 Financial Results Conference Call - ATEA PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2026 Financial Results and Business Update Conference Call. At this time, all participants are in a listening mode. Following the formal rem
- 2d agoAVIRHTGCAtea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules CapitalGlobeNewswireBOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
- 2d agoAVIRHTGCAtea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules CapitalGlobeNewswireBOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $200 million. The facility st ...
- 1w agoAVIRAtea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026GlobeNewswireBOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
- 1mo agoAVIRAtea Pharmaceuticals - ATEA PHARMACEUTICALS INCEarnings Call TranscriptsGreat. Hello, everyone. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.MorganStanley.com forwar
- 1mo agoAVIRAtea Pharmaceuticals - Morgan Stanley 24th Annual Global Healthcare Conference - ATEA PHARMACEUTICALS INCEarnings Call TranscriptsGreat. Hello, everyone. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.MorganStanley.com forwar
- 2mo agoAVIRAtea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireBOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
- 3mo agoAVIRAtea Pharmaceuticals Second Quarter 2026 Earnings - ATEA PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 2026 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal
- 3mo agoAVIRAtea Pharmaceuticals Second Quarter 2026 Earnings - ATEA PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 2026 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal
- 3mo agoAVIRAtea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3
- 3mo agoAVIRAtea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026GlobeNewswireBOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
- 3mo agoAVIRAtea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C VirusGlobeNewswireBemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa®), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a
- 4mo agoAVIRAtea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E VirusGlobeNewswirePhase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No
- 4mo agoAVIRAtea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusGlobeNewswireTopline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global
- 5mo agoAVIRAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026GlobeNewswireBOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
- 6mo agoAVIRAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis PipelineGlobeNewswireBOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
- 6mo agoAVIRAtea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireC-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to
- 6mo agoAVIRAtea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026GlobeNewswireBOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
- 7mo agoAVIRCOYAReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COOBusiness WireAdditions Bring Extensive Capital Markets and Business Transaction Expertise to Company as it Advances Pegtarazimod into Late-Stage Clinical Trials ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company
- 8mo agoAVIRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireAdvanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America
- 8mo agoAVIRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026GlobeNewswireBOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
- 8mo agoAVIRAtea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026GlobeNewswireResults Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc.
- 10mo agoAVIRAtea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusGlobeNewswireEnrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America,
- 11mo agoAVIRCOYAReAlta Life Sciences Appoints Dr. Howard Berman as Executive ChairmanBusiness WireReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of
- 11mo agoAVIRAtea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare ConferenceGlobeNewswireBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 12mo agoAVIRAtea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePatient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against
- 1y agoAVIRAtea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025GlobeNewswireBOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025GlobeNewswireBOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025GlobeNewswireBOSTON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025GlobeNewswireBOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoAVIRAtea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewswireBOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAVIRAtea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePatient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98%
- 1y agoAVIRAtea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025GlobeNewswireBOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North AmericaGlobeNewswireC-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short
- 1y agoAVIRAtea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireEnrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential
- 1y agoAVIRAtea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025GlobeNewswireFull Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for
- 1y agoAVIRAtea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025GlobeNewswirePanel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and
- 1y agoAVIRAtea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025GlobeNewswireBOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRCOYAAtea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase ProgramGlobeNewswireBOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
- 1y agoAVIRAtea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusGlobeNewswireRegimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with
- 1y agoAVIRAtea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder ValueGlobeNewswireBOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals Issues Statement Regarding Director NominationsGlobeNewswireBOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025GlobeNewswireBOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics
- 1y agoAVIRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireSuccessful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30
- 1y agoAVIRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025GlobeNewswireBOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for